“CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety” (2026) Journal of Medical Sciences, 21(2), pp. 30–35. doi:10.51984/szn7cg42.